← Back to Search

MBT in liver disease for Tricuspid Atresia (MBT+Fontan Trial)

N/A
Waitlist Available
Led By Daniel R Ganger, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

MBT+Fontan Trial Summary

This trial will assess a non-invasive functional liver test in patients with the Fontan circulation that may be used for prognostic purposes.

Eligible Conditions
  • Tricuspid Atresia
  • Dilated Cardiomyopathy

MBT+Fontan Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MR Elastography Results Compared to Methacetin Breath Test Results in Patients Undergoing Heart and Liver Transplant Evaluation.
Methacetin Breath Test Results in Patients Undergoing Heart and Liver Transplant Evaluation.
To Explore Any Association Between MBT Parameter and Clinical Parameters Already Available Per Standard of Care in Patients Undergoing Heart and Liver Transplant Evaluation.

MBT+Fontan Trial Design

1Treatment groups
Experimental Treatment
Group I: MBT in liver diseaseExperimental Treatment1 Intervention
Methacetin Breath test (MBT) intervention. We will use the MBT test to measure time from administration of 13C methacetin to obtaining the peak elimination of 13CO2.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,600 Previous Clinical Trials
915,508 Total Patients Enrolled
Daniel R Ganger, MDPrincipal InvestigatorNorthwestern University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease
Daniel Ganger 2019. "Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04176458.
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top